enGene Initiates LEGEND Study of EG-70 in BCG-Unresponsive NMIBC Patients
The LEGEND study will evaluate the safety and efficacy of EG-70 in patients with BCG-unresponsive NMIBC.
Published: July 27, 2026
Updated: July 27, 2026
Author: Humanexa Intelligence
Therapeutic area: Urology / Bladder Cancer
Asset: enGene
Trial SummaryCLN
Phase III
Urology / Bladder Cancer
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The initiation of the LEGEND study for EG-70 represents a significant development in the treatment landscape for BCG-unresponsive NMIBC patients. If successful, it could provide enGene with a competitive edge in oncology and address an unmet medical need in a challenging patient population.
Recommended action
Humanexa recommends Monitor.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.